checkAd

Pherecydes Pharma Announces Its 2020 Annual Financial Results and Confirms Its 2021 Outlook

Nachrichtenquelle: Business Wire (engl.)
15.04.2021, 07:00  |  168   |   |   

Regulatory News:

Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces its annual results for the year to December 31, 2020 and confirms its development prospects for 2021.

Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, states: “Thanks to the resounding success of our Initial Public Offering, we are accelerating the strategic investments in our R&D and clinical programs. This ramping up is being accompanied by an ongoing very active intellectual property policy that has recently led to the granting of two new strategic patents in the United States. At the same time, our phages are continuing to be used within the framework of compassionate use by additional hospitals in France, and we are eager to provide a broader response to this growing medical need once we are granted an Early Access Program, which is expected during the second half of this year. Given these achievements and the clinical potential of our three classes of phages targeting some of the most resistant bacteria, Pherecydes has numerous assets that should enable us to establish ourselves as a key player in precision phage therapy.

2020 annual results

Simplified income statement1 (in euros)

2020

2019

Operating income

1,863,286

2,327,798

Operating expenses

5,289,693

5,018,850

Operating profit/loss

- 3,426,407

- 2,691,051

Financial result

- 3,517

- 1,625

Exceptional income

1,620,852

442,670

Net profit/loss

- 1,395,340

- 1,221,868

______________________
1 Annual accounts were approved by the Board on April 14, 2021. Audit procedures relative to these accounts have been carried out, and the statutory auditor’s certification report is pending.

Seite 1 von 4
Pherecydes Pharma SADIR Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Pherecydes Pharma Announces Its 2020 Annual Financial Results and Confirms Its 2021 Outlook Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces its annual results for the year to …

Nachrichten des Autors

Titel
Titel
Titel
Titel